우수사례 | Best Practice and Cases in Lottery and Gambling | 最佳实践
- date : 2015-05-20 01:10|hit : 2585
-
- Article; Proceedings Paper] Bisphosphonates: Clinical experience
-
DocNo of ILP: 5784
Doc. Type: Article; Proceedings Paper
Title: Bisphosphonates: Clinical experience
Authors: Coleman, RE
Full Name of Authors: Coleman, RE
Keywords by Author: bone metastases; phase III; zoledronic acid; pamidronate; skeletal complications
Keywords Plus: PLACEBO-CONTROLLED TRIAL; BREAST-CANCER PATIENTS; LONG-TERM EFFICACY; REFRACTORY PROSTATE-CANCER; ADVANCED MULTIPLE-MYELOMA; METASTATIC BONE-DISEASE; SKELETAL COMPLICATIONS; ZOLEDRONIC ACID; DOUBLE-BLIND; ORAL CLODRONATE
Abstract: Bone is a preferred site of metastasis for many solid tumors, and the complications associated with bone metastases can result in significant skeletal morbidity including severe bone pain, pathologic fracture, spinal cord compression, and hypercalcemia of malignancy (HCM). Bisphosphonates are the current standard of care for preventing skeletal complications associated with bone metastases. Clinical trials investigating the benefit of bisphosphonate therapy have used a composite end point defined as a skeletal-related event (SRE) or bone event, which typically includes pathologic fracture, spinal cord compression, radiation or surgery to bone, and HCM. Bisphosphonates have been shown to significantly reduce the incidence of these events in patients with bone metastases. Zoledronic acid (Zometa(R); Novartis Pharmaceuticals Corp.; East Hanover, NJ), pamidronate (Aredia(R); Novartis Pharmaceuticals Corp.), clodronate (Bonefos'; Anthra Pharmaceuticals; Princeton, NJ), and ibandronate (Bondronat(R); Hoffmann-La Roche,Inc.; Nutley, NJ) all have demonstrated efficacy superior to that of placebo in patients with breast cancer. Zoledronic acid is the only bisphosphonate that has been compared directly with pamidronate, and it was shown by multiple event analysis to be significantly more effective at reducing the risk of an SIZE. In patients with prostate cancer, clodronate, etidronate (Didronel(R); Procter and Gamble Pharmaceuticals, Inc.; Cincinnati, OH), and pamidronate have demonstrated transient palliation of bone pain. However, zoledronic acid is the only bisphosphonate to demonstrate both significant and sustained pain reduction and a significantly lower incidence and longer time to onset of SREs compared with placebo. Zoledronic acid is also the only bisphosphonate to demonstrate efficacy in patients with bone metastases from a variety of other solid tumors, including lung cancer and renal cell carcinoma. In conclusion, bisphosphonates effectively reduce skeletal complications in patients with bone metastases from breast cancer, and zoledronic acid has demonstrated the broadest clinical activity in patients with a wide variety of tumor types.
Cate of OECD: Clinical medicine
Year of Publication: 2004
Business Area: other
Detail Business: medicine & science
Country: USA
Study Area:
Name of Journal: ONCOLOGIST
Language: English
Country of Authors: Weston Pk Hosp, Ctr Canc Res, Acad Unit Clin Oncol, Sheffield S10 2SJ, S Yorkshire, England
Press Adress: Coleman, RE (reprint author), Weston Pk Hosp, Ctr Canc Res, Acad Unit Clin Oncol, Whitham Rd, Sheffield S10 2SJ, S Yorkshire, England.
Email Address: r.e.coleman@sheffield.ac.uk
Citaion:
Funding:
Lists of Citation: ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Berenson JR, 1998, J CLIN ONCOL, V16, P593; Body JJ, 2004, BRIT J CANCER, V90, P1133, DOI 10.1038/sj.bjc.6601663; Body JJ, 2003, ANN ONCOL, V14, P1399, DOI 10.1093/annonc/mdg367; COLEMAN R, 2004, 7 WORKSH BISPH LAB P; Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2001.0210; Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.3.CO;2-Z; Conte P, 2004, ONCOLOGIST, V9, P28, DOI 10.1634/theoncologist.9-90004-28; Conte PF, 1996, J CLIN ONCOL, V14, P2552; Cook RJ, 1996, BIOMETRICS, V52, P1311, DOI 10.2307/2532846; Dearnaley DP, 2003, J NATL CANCER I, V95, P1300, DOI 10.1093/jnci/djg038; DEMERS LM, 2003, CLIN ORTHOP S, V415, pS138, DOI 10.1097/01.blo0000092979.12414.54; Demers Laurence M., 2000, Cancer, V88, P2919, DOI 10.1002/1097-0142(20000615)88:12+<2919::AID-CNCR7>3.0.CO;2-Z; ELOMAA I, 1992, International Urology and Nephrology, V24, P159, DOI 10.1007/BF02549644; Ernst DS, 2003, J CLIN ONCOL, V21, P3335, DOI 10.1200/JCO.2003.03.042; FERLAY J, 2001, 5 IARC CANCERBASE; Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414; Garnero P, 2000, BRIT J CANCER, V82, P858, DOI 10.1054/bjoc.1999.1012; Ghosh D, 2000, BIOMETRICS, V56, P554, DOI 10.1111/j.0006-341X.2000.00554.x; Green JR, 2002, DRUG DEVELOP RES, V55, P210, DOI 10.1002/ddr.10071; GREEN JR, 1994, J BONE MINER RES, V9, P745; HILLNER BE, 2004, J CLIN ONCOL, V22, P1351; Hortobagyi GN, 1998, J CLIN ONCOL, V16, P2038; Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401; Hultborn R, 1999, ANTICANCER RES, V19, P3383; Johnson JR, 2003, J CLIN ONCOL, V21, P1404, DOI 10.1200/JCO.2003.08.072; KOHNO N, 2004, 40 ANN M AM SOC CLIN; Kristensen B, 1999, J INTERN MED, V246, P67, DOI 10.1046/j.1365-2796.1999.00507.x; Kylmala T, 1997, BRIT J CANCER, V76, P939, DOI 10.1038/bjc.1997.488; Lipton A, 2002, CANCER INVEST, V20, P45, DOI 10.1081/CNV-120014886; Lipton A, 2004, WHAT NEW BISPH 7 WOR; Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z; MAJOR PP, 2004, 7 WORKSH BISPH LAB P; MAJOR PP, 2003, P AN M AM SOC CLIN, V22, P762; Major PP, 2002, AM J CLIN ONCOL-CANC, V25, pS10, DOI 10.1097/00000421-200212001-00003; MASON MD, 2004, P AM SOC CLIN ONCOL, V16; PATERSON AHG, 1993, J CLIN ONCOL, V11, P59; PAVLAKIS N, 2004, COCHRANE LIB; Rosen LS, 2003, CANCER, V98, P1735, DOI 10.1002/cncr.11701; Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308; Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892; ROSS JR, 2003, BRIT MED J, V327, P1; Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141; SAAD F, 19 C EUR ASS UR 24 2; Saad F, 2002, J NATL CANCER I, V94, P1458; Saad F, 2003, J UROLOGY, V169, P394; Small EJ, 2003, J CLIN ONCOL, V21, P4277, DOI 10.1200/JCO.2003.05.147; SMITH JA, 1989, J UROLOGY, V141, P85; Strang P, 1997, ANTICANCER RES, V17, P4717; Theriault RL, 1999, J CLIN ONCOL, V17, P846; Tubiana-Hulin M, 2001, B CANCER, V88, P701; Weinfurt KP, 2002, ANN ONCOL, V13, P180; Williams Grant, 2004, J Biopharm Stat, V14, P5, DOI 10.1081/BIP-120028503; WINDELER J, 1995, BRIT MED J, V310, P454; Zekri J, 2001, INT J ONCOL, V19, P379
Number of Citaion: 55
Publication: ALPHAMED PRESS
City of Publication: MIAMISBURG
Address of Publication: ONE PRESTIGE PLACE, STE 290, MIAMISBURG, OH 45342-3758 USA
ISSN: 1083-7159
29-Character Source Abbreviation: ONCOLOGIST
ISO Source Abbreviation: Oncologist
Volume: 9
Version:
Start of File: 14
End of File: 27
DOI: 10.1634/theoncologist.9-90004-14
Number of Pages: 14
Web of Science Category: Oncology
Subject Category: Oncology
Document Delivery Number: 863GZ
Unique Article Identifier: WOS:000224550500003
[이 게시물은 HyeJung Mo…님에 의해 2015-05-20 20:27:31 GAMBLING에서 이동 됨]
- reply : 0
-
- list
-
- prev
- next